CUSIP: 62957M104
Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / SPONSORED ADR
-
Total 13F shares
-
14,939,633
-
Share change
-
+3,243,265
-
Total reported value
-
$88,999,000
-
Price per share
-
$5.96
-
Number of holders
-
24
-
Value change
-
+$19,022,694
-
Number of buys
-
13
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 62957M104?
CUSIP 62957M104 identifies NBRV - NABRIVA THERAPEUTICS AG - SPONSORED ADR in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2017
-
Previous quarter:
Q3 2016
Recent filing periods for CUSIP 62957M104:
Institutional Holders of NABRIVA THERAPEUTICS AG - SPONSORED ADR (NBRV) as of Q4 2016
As of 31 Dec 2016,
NABRIVA THERAPEUTICS AG - SPONSORED ADR (NBRV) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,939,633 shares.
The largest 10 holders included
Vivo Capital, LLC, Novo A/S, WELLINGTON MANAGEMENT GROUP LLP, ORBIMED ADVISORS LLC, Omega Fund Management, LLC, ACUTA CAPITAL PARTNERS, LLC, Hillhouse Capital Management, Ltd., Rock Springs Capital Management LP, BAKER BROS. ADVISORS LP, and Tekla Capital Management LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.